UCB SA (UCBJY)
| Market Cap | 54.52B +52.5% |
| Revenue (ttm) | 9.09B +25.8% |
| Net Income | 1.83B +46.3% |
| EPS | 9.43 +46.5% |
| Shares Out | n/a |
| PE Ratio | 29.80 |
| Forward PE | 22.98 |
| Dividend | 0.53 (0.36%) |
| Ex-Dividend Date | May 5, 2026 |
| Volume | 4,913 |
| Open | 144.79 |
| Previous Close | 144.14 |
| Day's Range | 140.78 - 144.79 |
| 52-Week Range | 89.00 - 168.76 |
| Beta | 0.19 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Jul 30, 2026 |
About UCB SA
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson’s disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for... [Read more]
Financial Performance
In 2025, UCB SA's revenue was 7.74 billion, an increase of 25.83% compared to the previous year's 6.15 billion. Earnings were 1.56 billion, an increase of 46.29%.
Financial numbers in EUR Financial StatementsNews
UCB downgraded to Equal Weight from Overweight at Barclays
Barclays analyst Charles Pitman-King downgraded UCB (UCBJF) to Equal Weight from Overweight with a price target of EUR 300, down from EUR 310. The firm cites the company’s growth investments…
Wafra to Acquire Navitas Credit Corp from UCB for $1.9 Billion
Wafra to Acquire Navitas Credit Corp from UCB for $1.9 Billion
United Community Banks (UCB) to Sell Equipment Finance Business for $1.9B
United Community Banks (UCB) to Sell Equipment Finance Business for $1.9B
United Community Banks Agrees To Sell Equipment Finance Business For $1.9 Bln
(RTTNews) - United Community Banks, Inc. (UCB), a bank holding company, Friday announced that it has agreed to sell its equipment finance business, consisting of Navitas Credit Corp. and NLFC Reinsura...
UCB SA Transcript: Investor update
BE BOLD demonstrated bimekizumab's statistically significant superiority over risankizumab in joint outcomes for psoriatic arthritis, with sustained efficacy and a safety profile consistent with prior studies. The results are expected to influence clinical guidelines, prescribing practices, and payer dynamics, supporting bimekizumab's positioning as a first-line therapy.
UCB SA Slides: Investor update
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
United Community Banks Inc (UCB) Stock Up 3.0% but GF Value Says Overvalued -- GF Score: 65/100
United Community Banks Inc (UCB) Stock Up 3.0% but GF Value Says Overvalued -- GF Score: 65/100
Biogen And UCB Present Positive PHOENYCS GO Data For DZP In Treating Lupus
(RTTNews) - Biogen Inc. (BIIB), a biotechnology company, and UCB SA (UCB.BR), a biopharmaceutical company, on Thursday released clinical data from the PHOENYCS GO program, including Phase 3 PHOENYCS r...
Cullinan jumps after UCB acquires Candid Therapeutics
Shares of Cullinan Therapeutics (CGEM) are moving higher after UCB (UCBJF) announced an agreement to acquire privately held Candid Therapeutics. Cizutamig, Candid’s lead investigational asset, is “pos...
UCB to Buy Candid Therapeutics for Up to $2.2 Billion
The deal seeks to bolster the company's pipeline of experimental treatments for autoimmune and inflammatory diseases.
Belgian pharma group UCB to buy Candid Therapeutics for up to $2.2 billion
Belgian biopharmaceuticals company UCB has agreed to buy privately-held Candid Therapeutics in a deal worth up to $2.2 billion, the companies said on Sunday.
UCB SA Slides: Acquisition presentation
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on May 3, 2026.
UCB to acquire Neurona Therapeutics
UCB (UCBJF) announced that it has entered into a definitive agreement under which UCB would acquire Neurona Therapeutics, including lead asset NRTX-1001, adding to UCB’s epilepsy portfolio. Neurona Th...
UCB downgraded to Equal Weight from Overweight at Morgan Stanley
Morgan Stanley analyst Sarita Kapila downgraded UCB (UCBJF) to Equal Weight from Overweight with an unchanged price target of EUR 260. The firm sees a balanced risk/reward at current share…
Belgium's UCB in autoimmune drug deal with Antengene
Belgian drugmaker UCB has entered into an agreement to licence Antengene's experimental autoimmune disease therapy ATG-201 and associated technology, paying $60 million up front and over $1.1 billio...
UCB SA Earnings Call Transcript: H2 2025
Net sales surged 35% year-over-year, led by Bimzelx and four other growth drivers, with strong pipeline progress and a robust financial position. 2026 guidance anticipates continued high single to low double-digit revenue growth and margin expansion, supported by strategic investments and portfolio differentiation.
UCB SA Annual report: H2 2025
UCB SA has published its H2 2025 annual report on February 26, 2026.
UCB SA Slides: H2 2025
UCB SA has posted slides in relation to its H2 2025 quarterly earnings report, which was published on February 26, 2026.
UCB initiated with an Outperform at Wolfe Research
Wolfe Research analyst Rudy Li initiated coverage of UCB (UCBJF) with an Outperform rating and EUR 340 price target The firm launched coverage of the neuroscience biotech sector with a…
UCB price target raised to EUR 304 from EUR 255 at Goldman Sachs
Goldman Sachs raised the firm’s price target on UCB (UCBJF) to EUR 304 from EUR 255 and keeps a Buy rating on the shares.
UCB SA Transcript: 44th Annual J.P. Morgan Healthcare Conference
A decade of growth is anticipated, driven by five key products in immunology and neurology, robust R&D investment, and a strong pipeline. Market access for BIMZELX is expanding, with new indications and head-to-head studies expected to fuel further growth.
UCB SA Slides: 44th Annual J.P. Morgan Healthcare Conference
UCB SA has posted slides in relation to its latest quarterly earnings report, which was published on January 14, 2026.
UCB price target raised to EUR 310 from EUR 270 at Barclays
Barclays raised the firm’s price target on UCB (UCBJF) to EUR 310 from EUR 270 and keeps an Overweight rating on the shares.
UCB price target raised to EUR 295 from EUR 285 at Deutsche Bank
Deutsche Bank raised the firm’s price target on UCB (UCBJF) to EUR 295 from EUR 285 and keeps a Buy rating on the shares.
UCB price target raised to EUR 300 from EUR 230 at JPMorgan
JPMorgan raised the firm’s price target on UCB (UCBJF) to EUR 300 from EUR 230 and keeps an Overweight rating on the shares.